NCT02111603View on ClinicalTrials.gov

Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids

PHASE4CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2015

Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
DRUG

Colesevelam

Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT02111603 - Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids | Biotech Hunter | Biotech Hunter